Limantrafin
Tier C — Watch / tradeLimantrafin
Targets：Not applicable
Indications (approved)：Adenoid cystic carcinoma, Leukaemia, Acute lymphoblastic leukaemia, Breast cancer, Solid tumour, Haematological malignancy, Non-Hodgkin lymphoma, Hepatocellular carcinoma
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| CB-103-001 | 98-54-4 | 4-(tert-butyl)phenol |
| CB-103-002 | 4548-45-2 | 2-chloro-5-nitropyridine |
| CB-103-003 | 218456-68-9 | 2-(4-(tert-butyl)phenoxy)-5-nitropyridine |
| CB-103 | 218457-67-1 | 3-Pyridinamine, 6-[4-(1,1-dimethylethyl)phenoxy]- |
Frequently asked questions
What are the approved indications of Limantrafin?
Approved indications include: Adenoid cystic carcinoma, Leukaemia, Acute lymphoblastic leukaemia, Breast cancer, Solid tumour, Haematological malignancy, Non-Hodgkin lymphoma, Hepatocellular carcinoma.
When does the Limantrafin patent expire?
No public expiry year is available for Limantrafin yet; this page updates once verified.
How many synthesis routes are recorded for Limantrafin?
1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Limantrafin intermediates?
All intermediates in Limantrafin routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Limantrafin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09